Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × Positron-Emission Tomography × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 6 Lymphoma, Non-Hodgkin 3 Neoplasms 2 Neoplasm Metastasis 2 Lymphoma 2 Disease 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vulvar Diseases 1 Vasculitis 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Smoking Cessation 1 Papillomavirus Infections 1 Osteomyelitis 1 Nose Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Pulmonary Nodules 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia 1

Interventions

Ipilimumab 79 pembrolizumab 71 Nivolumab 68 aldesleukin 46 Cyclophosphamide 44 Interleukin-2 33 fludarabine phosphate 30 Vemurafenib 29 Dacarbazine 28 trametinib 25 fludarabine 25 dabrafenib 25 Temozolomide 21 Bevacizumab 15 Radiosurgery 14 binimetinib 12 Paclitaxel 12 Introns 12 Interferon alpha-2 12 Carboplatin 11 CTLA-4 Antigen 11 peginterferon alfa-2b 9 montanide ISA 51 9 encorafenib 9 cobimetinib 9 Radiotherapy 9 talimogene laherparepvec 8 atezolizumab 8 Sorafenib 8 spartalizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236546 2017-04-13

FDG-PET in Advanced Melanoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated

3 enrolled 4 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡